Divergence in Fitness and Evolution of Drug Resistance in Experimental Populations of Candida albicans

ABSTRACT The dissemination and persistence of drug-resistant organisms in nature depends on the relative fitness of sensitive and resistant genotypes. While resistant genotypes are expected to be at an advantage compared to less resistant genotypes in the presence of drug, resistance may incur a cost; resistant genotypes may be at a disadvantage in the absence of drug. We measured the fitness of replicate experimental populations of the pathogenic yeastCandida albicans founded from a single progenitor cell in a previous study (L. E. Cowen, D. Sanglard, D. Calabrese, C. Sirjusingh, J. B. Anderson, and L. M. Kohn, J. Bacteriol. 182:1515–1522, 2000) and evolved in the presence, and in the absence, of the antifungal agent fluconazole. Fitness was measured both in the presence and in the absence of fluconazole by placing each evolved population in direct competition with the drug-sensitive ancestor and measuring the reproductive output of each competitor in the mixture. Populations evolved in the presence of drug diverged in fitness. Any significant cost of resistance, indicated by reduced fitness in the absence of drug, was eliminated with further evolution. Populations evolved in the absence of drug showed more uniform increases in fitness under both conditions. Fitness in the competition assays was not predicted by measurements of the MICs, doubling times, or stationary-phase cell densities of the competitors in isolation, suggesting the importance of interactions between mixed genotypes in competitions.

[1]  D. Andersson,et al.  The cost of antibiotic resistance from a bacterial perspective. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[2]  Richard E. Lenski,et al.  Long-Term Experimental Evolution in Escherichia coli. II. Changes in Life-History Traits During Adaptation to a Seasonal Environment , 1994, The American Naturalist.

[3]  S. Paulous,et al.  Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. , 1996, The Journal of general virology.

[4]  K. Crandall,et al.  Parallel evolution of drug resistance in HIV: failure of nonsynonymous/synonymous substitution rate ratio to detect selection. , 1999, Molecular biology and evolution.

[5]  S. Levy Balancing the drug-resistance equation. , 1994, Trends in microbiology.

[6]  E. Anaissie Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  B. Levin,et al.  The biological cost of antibiotic resistance. , 1999, Current opinion in microbiology.

[8]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[9]  M Travisano,et al.  Long-term experimental evolution in Escherichia coli. IV. Targets of selection and the specificity of adaptation. , 1996, Genetics.

[10]  S. Wright Surfaces of Selective Value Revisited , 1988, The American Naturalist.

[11]  P. T. Magee,et al.  Recent developments in molecular genetics of Candida albicans. , 2000, Annual review of microbiology.

[12]  R. Anderson,et al.  The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  M. Milgroom,et al.  Lack of correlation between fitness and resistance to sterol biosynthesis-inhibiting fungicides in Pyrenophora teres , 1994 .

[14]  B. Levin,et al.  Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. , 2000, Genetics.

[15]  R. Lenski,et al.  Long-Term Experimental Evolution in Escherichia coli. I. Adaptation and Divergence During 2,000 Generations , 1991, The American Naturalist.

[16]  T. C. White,et al.  Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance , 1998, Clinical Microbiology Reviews.

[17]  P. Melgarejo,et al.  Fitness of Botrytis cinerea Associated with Dicarboximide Resistance. , 2000, Phytopathology.

[18]  J. E. Bouma,et al.  Evolution of a bacteria/plasmid association , 1988, Nature.

[19]  J. Bull,et al.  Mice Are Not Furry Petri Dishes , 2000, Science.

[20]  T. Leitner,et al.  Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Cowen,et al.  Evolution of Drug Resistance in Experimental Populations of Candida albicans , 2000, Journal of bacteriology.

[22]  M. Ghannoum,et al.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. O'Brien,et al.  The global epidemic nature of antimicrobial resistance and the need to monitor and manage it locally. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  C. Paquin,et al.  Relative fitness can decrease in evolving asexual populations of S. cerevisiae , 1983, Nature.

[25]  Sewall Wright,et al.  CHARACTER CHANGE, SPECIATION, AND THE HIGHER TAXA , 1982, Evolution; international journal of organic evolution.

[26]  A. F. Bennett,et al.  Experimental tests of the roles of adaptation, chance, and history in evolution. , 1995, Science.

[27]  N. Georgopapadakou,et al.  Human mycoses: drugs and targets for emerging pathogens. , 1994, Science.

[28]  N. Georgopapadakou,et al.  Antifungals: mechanism of action and resistance, established and novel drugs. , 1998, Current opinion in microbiology.

[29]  O. Berg,et al.  Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. , 2000, Science.

[30]  S. Levy,et al.  The impact of antibiotic use on resistance development and persistence. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[31]  R. Korona Genetic divergence and fitness convergence under uniform selection in experimental populations of bacteria. , 1996, Genetics.

[32]  F. Cohan,et al.  AMELIORATION OF THE DELETERIOUS PLEIOTROPIC EFFECTS OF AN ADAPTIVE MUTATION IN BACILLUS SUBTILIS , 1994, Evolution; international journal of organic evolution.

[33]  S. Levin,et al.  Disease transmission dynamics and the evolution of antibiotic resistance in hospitals and communal settings. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[34]  M. D. Waard,et al.  Fitness of isolates of Erysiphe graminis f.sp. tritici with reduced sensitivity to fenpropimorph. , 1996 .

[35]  B. Levin,et al.  Adaptation to the fitness costs of antibiotic resistance in Escherichia coli , 1997, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[36]  T. C. White,et al.  The Trailing End Point Phenotype in Antifungal Susceptibility Testing Is pH Dependent , 1999, Antimicrobial Agents and Chemotherapy.

[37]  R. Lenski,et al.  The cost of antibiotic resistance--from the perspective of a bacterium. , 2007, Ciba Foundation symposium.

[38]  R. Lenski,et al.  Dynamics of adaptation and diversification: a 10,000-generation experiment with bacterial populations. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. M. Stewart,et al.  The population genetics of antibiotic resistance. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  C. Boucher,et al.  Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. , 1999, AIDS.

[41]  T. G. Mitchell,et al.  Clonal and Spontaneous Origins of Fluconazole Resistance in Candida albicans , 2000, Journal of Clinical Microbiology.

[42]  P. T. Magee,et al.  Single-Copy IMH3 Allele Is Sufficient To Confer Resistance to Mycophenolic Acid in Candida albicans and To Mediate Transformation of Clinical Candida Species , 2001, Infection and Immunity.

[43]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.